Dual Therapy With Interferon Beta-1b and Clofazimine for COVID-19
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04465695|
Recruitment Status : Unknown
Verified July 2020 by Ivan FN Hung MD, The University of Hong Kong.
Recruitment status was: Recruiting
First Posted : July 10, 2020
Last Update Posted : July 15, 2020
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|COVID-19||Drug: Interferon beta-1b Drug: Clofazimine||Phase 2|
The novel coronavirus (SARS-CoV-2), is a single-stranded RNA coronavirus. The virus was first isolated from patients presented with pneumonia in Wuhan in December 2019.Sequences of the Wuhan betacoronavirus show similarities to betacoronaviruses found in bats, sharing a common ancestor with the 2003 SARS coronavirus (SARS-CoV) and the bat coronavirus HKU9-1, a virus found in fruit bats. Similar to SARS-CoV, it is a member of Beta-CoV lineage B. Five genomes of the novel coronavirus have been initially isolated and reported including BetaCoV/Wuhan/IVDC-HB-01/2019, BetaCoV/Wuhan/IVDC-HB-04/2020, BetaCoV/Wuhan/IVDC-HB-05/2019, BetaCoV/Wuhan/WIV04/2019, and BetaCoV/Wuhan/IPBCAMS-WH-01/2019 from the China CDC.
The SARS-CoV-2 has since spread from China to the rest of the world. As of 1 July 2020, more than 10 million people been confirmed to have infected by SARS-CoV-2, resulting in more than 500,000 deaths. No specific antiviral treatment for the SARS-CoV-2 is currently available, but existing medication could be repurposed.
Genetic sequencing demonstrated similarity of the SARS-CoV-2 to the SARS-CoV and MERS CoV.2 We expect patients infected with the SARS-CoV-2 will also present similarly with initial upper respiratory tract symptoms including fever, cough, sputum, myalgia and shortness or breath. More severe cases might complicate with pneumonia and required ventilatory or ECMO support. According to our previous studies in 2003 on patients hospitalized for severe SARS-CoV, the viral load peaked between day 7 from symptoms onset and coincided with clinical deterioration of pneumonia and respiratory failure, with majority of the patients required intensive care support. Higher viral load isolated from different human system also correlated with worsened SARS manifestation and complications.
Previously, the investigators have demonstrated that interferon β-1b, commonly used in the treatment of multiple sclerosis and lopinavir/ ritonavir, also demonstrated to improve the outcome of MERS-CoV infection in a non-human primate model of common marmoset.7
More recently, the investigators have demonstrated that the triple combination of interferon β-1b, lopinavir/ ritonavir and ribavirin was significantly more effective in alleviating symptoms and respiratory SARS-CoV-2 viral load than lopinavir/ ritonavir with ribavirin or lopinavir/ ritonavir alone, suggesting that interferon β-1b might be the most potent antiviral among the three.
Another in-vitro study on an oral antimicrobial clofazimine for treatment of non-tuberculous mycobacterium infection has been proven to reduce SARS-CoV-2 viral load.
Therefore, the investigators propose to perform a prospective open-label randomised controlled trial among adult patients hospitalised after July 2020 for virologically confirmed SARS-CoV-2 infection. Patients will be randomly assigned to one of the three groups: group A: a 3-day course of 3 doses of subcutaneous injection of interferon β-1b 1mL (0.5mg; 16 million IU) consecutively on day 1 to day 3 and oral clofazimine 100mg twice daily on day 1, then 100mg daily for 2 days plus standard care, or group B: oral clofazimine 100mg twice daily on day 1, then 100mg daily for 2 days plus standard care, or group C: standard care alone (1:1:1).
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||81 participants|
|Intervention Model:||Parallel Assignment|
|Intervention Model Description:||Open-label randomised controlled trial|
|Masking:||None (Open Label)|
|Official Title:||An Open-label Randomised Controlled Trial on Dual Therapy With Interferon Beta-1b and Clofazimine Combination, as Treatment for COVID-19 Infection|
|Actual Study Start Date :||July 14, 2020|
|Estimated Primary Completion Date :||June 30, 2021|
|Estimated Study Completion Date :||September 30, 2021|
Experimental: IFN beta-1b and clofazimine
A 3-day course of 3 doses of subcutaneous injection of interferon β-1b 1mL (0.5mg; 16 million IU) consecutively on day 1 to day 3 and oral clofazimine 100mg twice daily on day 1, then 100mg daily for 2 days plus standard care
Drug: Interferon beta-1b
Subcutaneous injection of interferon β-1b 1mL (0.5mg; 16 million IU) for 3 days
Oral 100mg twice daily on day 1, then 100mg daily for 2 days
Active Comparator: Clofazimine
A 3-day course of oral clofazimine 100mg twice daily on day 1, then 100mg daily for 2 days plus standard care
Oral 100mg twice daily on day 1, then 100mg daily for 2 days
No Intervention: Control
Standard care alone
- Clinical alleviation of symptoms [ Time Frame: 7 days ]Time to complete alleviation of symptoms as defined by NEWS of 0 maintained for 24 hours
- Hospitalisation [ Time Frame: 14 days ]Length of hospitalisation
- Time to negative viral load [ Time Frame: 7 days ]Time to negative nasopharyngeal swab, throat saliva and sputum viral load by RT-PCR
- Inflammatory changes [ Time Frame: 7 days ]Cytokine/ chemokine changes
- Mortality [ Time Frame: 30 days ]One month mortality rate
- Adverse events [ Time Frame: 30 days ]Adverse events during and shortly after treatment
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Recruited subjects include all adult patients 18 years or above hospitalized for virologic confirmed SARS-CoV-2 infection.
- All subjects give written informed consent. For patients who are critically ill, requiring ICU, ventilation or confused, informed consent will be obtained from spouse, next-of-kin or legal guardians.
- Subjects must be available to complete the study and comply with study procedures. Willingness to allow for serum samples to be stored beyond the study period, for potential additional future testing to better characterize immune response
- Inability to comprehend and to follow all required study procedures.
- Allergy or severe reactions to the study drugs
- Patients taking medication that will potentially interact with l interferon beta-1b or clofazimine
- Patients with known history of severe depression
- Received an experimental agent (vaccine, drug, biologic, device, blood product, or medication) within 1 month prior to recruitment in this study or expect to receive an experimental agent during this study.
- To participate in an unrelated trial during the current clinical trial. Nevertheless, the patients have the right to withdraw from the current clinical trial to join another clinical trial.
- Have a history of alcohol or drug abuse in the last 5 years.
- Have any condition that the investigator believes may interfere with successful completion of the study
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04465695
|Contact: Ivan FN Hung, MD FRCPfirstname.lastname@example.org|
|Contact: Kelvin KW To, MD FRCPathemail@example.com|
|China, Hong Kong|
|The University of Hong Kong, Queen Mary Hospital||Recruiting|
|Hong Kong, Hong Kong, China, 852|
|Contact: Ivan FN Hung, MD FRCP 852 22554049 firstname.lastname@example.org|
|Principal Investigator:||Ivan FN Hung, MD FRCP||HKU|
|Responsible Party:||Ivan FN Hung MD, Clinical Professor, The University of Hong Kong|
|Other Study ID Numbers:||
|First Posted:||July 10, 2020 Key Record Dates|
|Last Update Posted:||July 15, 2020|
|Last Verified:||July 2020|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||Yes|
|Plan Description:||To share anonymised participant data|
Statistical Analysis Plan (SAP)
Informed Consent Form (ICF)
Clinical Study Report (CSR)
|Time Frame:||Within 12 months of study published|
|Access Criteria:||To be approved by the HKU/ IRB clinical trial study panel of valid research purpose|
|Studies a U.S. FDA-regulated Drug Product:||No|
|Studies a U.S. FDA-regulated Device Product:||No|
Respiratory Tract Infections
RNA Virus Infections
Respiratory Tract Diseases
Physiological Effects of Drugs